Other names for axitinib
WebAxitinib is a targeted cancer drug. It is pronounced ak-sih-tih-nib. It is also called Inlyta. It is a treatment for kidney cancer that has spread (advanced kidney cancer). You usually have it … WebPregnancy Category D. Axitinib can cause fetal harm when administered to a pregnant woman based on its mechanism of action. There are no adequate and well-controlled …
Other names for axitinib
Did you know?
WebFeb 25, 2024 · Constipation, diarrhea, throwing up, and upset stomach are common with axitinib. If these happen, talk with your doctor about ways to lower these side effects. Call … WebIn vitro data indicate that axitinib is metabolised primarily by CYP3A4/5 and, to a lesser extent, CYP1A2, CYP2C19, and uridine diphosphate-glucuronosyltransferase (UGT) 1A1.. CYP3A4/5 inhibitors. Ketoconazole, a strong inhibitor of CYP3A4/5, administered at a dose of 400 mg once daily for 7 days, increased the mean area under the curve (AUC) 2-fold …
WebFeb 1, 2024 · Axitinib is a medication used to treat advanced renal cell carcinoma (RCC). This is a type of cancer that starts in the kidney cells. The axitinib brand name is Inlyta. Axitinib is typically prescribed when at least one other systemic treatment option or therapy has failed to provide results. In Bangladesh it is under the trade name Axinix. In Germany, Switzerland and other European countries it is available under the trade name Inlyta.
WebAlthough axitinib dose adjustment has not been studied in patients receiving strong CYP3A4/5 inhibitors, if a strong CYP3A4/5 inhibitor must be co-administered, a dose decrease of axitinib to approximately half the dose (e.g. the starting dose should be reduced from 5 mg twice daily to 2 mg twice daily) is recommended. WebGeneric Name Axitinib DrugBank Accession Number DB06626 Background. Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). 7 Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is …
WebOct 7, 2024 · Generic name: axitinib [ axIT-i-nib ] Brand name: Inlyta Dosage form: oral tablet (1 mg; 5 mg) Drug classes: Multikinase inhibitors, VEGF/VEGFR inhibitors. ... Other drugs …
WebAug 1, 2024 · Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial growth factor (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma. Axitinib therapy is … assida noisette sans glutenWebPage 3/8 Safety Data Sheet acc. to OSHA HCS Printing date 09/30/2024 Revision date 09/30/2024 Trade name:Axitinib (Contd. from page 2) 53.1.21 · After inhalation:Supply fresh air; consult doctor in case of complaints. · After skin contact:Generally the product does not irritate the skin. · After eye contact:Rinse opened eye for several minutes under running … lanka monk fruitWebFeb 25, 2024 · Constipation, diarrhea, throwing up, and upset stomach are common with axitinib. If these happen, talk with your doctor about ways to lower these side effects. Call your doctor right away if any of these effects bother you, do not go away, or get very bad. A very bad and sometimes deadly brain problem called posterior reversible encephalopathy ... lankamyymälätWebWithhold both axitinib and avelumab until these adverse reactions recover to Grade ≤1. If persistent (>5 days), consider corticosteroid therapy (initial dose of 0.5-1 mg/kg/day) … assi dokusWebInlyta is a medicine that contains the active substance axitinib. It is available as tablets (1, 3, 5 and 7 mg). What is Inlyta used for? Inlyta is used to treat adults with advanced renal cell carcinoma, a type of kidney cancer. ‘Advanced’ means that the cancer has started to spread. Inlyta is used when treatment with Sutent (sunitinib) or ... lankamission passportWebOct 12, 2024 · Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.. Some people taking … assida noisette maisonWebApr 10, 2024 · History of another primary malignancy other than RCC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%) Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live, attenuated vaccine will be required … assidelta broker